While the influence of metformin on STAT3 in endometrial cancer is unknown, metformin has been shown to inhibit STAT3-mediated cell proliferation in breast, esophageal, and bladder cancers [25–27]. Here, STAT3 is linked to urinary bladder carcinoma.